DOP2012000310A - Morfolinopirimidinas y su uso en terapia - Google Patents

Morfolinopirimidinas y su uso en terapia

Info

Publication number
DOP2012000310A
DOP2012000310A DO2012000310A DO2012000310A DOP2012000310A DO P2012000310 A DOP2012000310 A DO P2012000310A DO 2012000310 A DO2012000310 A DO 2012000310A DO 2012000310 A DO2012000310 A DO 2012000310A DO P2012000310 A DOP2012000310 A DO P2012000310A
Authority
DO
Dominican Republic
Prior art keywords
therapy
morpholinopirimidinas
processes
formula
preparation
Prior art date
Application number
DO2012000310A
Other languages
English (en)
Inventor
Kevin Michael Foote
Johannes Wilhelmus Maria Nissink
Paul Turner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2012000310A publication Critical patent/DOP2012000310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Se proporcionan compuestos pirimidinilicos de fórmula (l), donde: R2 es (l) o sales farmacéuticamente aceptables de estos, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
DO2012000310A 2010-06-11 2012-12-11 Morfolinopirimidinas y su uso en terapia DOP2012000310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35371310P 2010-06-11 2010-06-11

Publications (1)

Publication Number Publication Date
DOP2012000310A true DOP2012000310A (es) 2013-02-15

Family

ID=44168987

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000310A DOP2012000310A (es) 2010-06-11 2012-12-11 Morfolinopirimidinas y su uso en terapia

Country Status (38)

Country Link
US (5) US8252802B2 (es)
EP (1) EP2579877B1 (es)
JP (1) JP5721821B2 (es)
KR (1) KR101820996B1 (es)
CN (1) CN103068391B (es)
AR (1) AR081859A1 (es)
AU (1) AU2011263491B2 (es)
BR (1) BR112012031561B1 (es)
CA (1) CA2800203C (es)
CL (1) CL2012003503A1 (es)
CO (1) CO6640270A2 (es)
CR (1) CR20120628A (es)
CU (1) CU24109B1 (es)
DK (1) DK2579877T3 (es)
DO (1) DOP2012000310A (es)
EA (1) EA022087B1 (es)
EC (1) ECSP12012334A (es)
ES (1) ES2514325T3 (es)
GT (1) GT201200334A (es)
HK (1) HK1182019A1 (es)
HR (1) HRP20140953T1 (es)
MX (1) MX2012014477A (es)
MY (1) MY158193A (es)
NI (1) NI201200184A (es)
NZ (1) NZ604480A (es)
PE (1) PE20130306A1 (es)
PL (1) PL2579877T3 (es)
PT (1) PT2579877E (es)
RS (1) RS53566B1 (es)
SA (1) SA111320519B1 (es)
SG (1) SG185711A1 (es)
SI (1) SI2579877T1 (es)
SM (1) SMT201400146B (es)
TW (1) TWI526208B (es)
UA (1) UA109010C2 (es)
UY (1) UY33440A (es)
WO (1) WO2011154737A1 (es)
ZA (1) ZA201300255B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
RS59054B1 (sr) 2014-06-17 2019-08-30 Vertex Pharma Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2018029117A1 (en) * 2016-08-10 2018-02-15 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) New atr inhibitors for the use in cancer therapy
WO2018153969A1 (en) 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
JP7159307B2 (ja) 2017-07-13 2022-10-24 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
CN111886224A (zh) * 2017-08-17 2020-11-03 德州大学系统董事会 Atr激酶的杂环抑制剂
EP3679041B1 (en) 2017-09-08 2022-07-06 Newave Pharmaceutical Inc. Substituted pyrrolopyridines as atr inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3084863A1 (en) 2017-12-08 2019-06-13 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
SI3753937T1 (sl) 2018-02-07 2024-03-29 Wuxi Biocity Biopharmaceutics Co., Ltd. Atr inhibitor in njegova uporaba
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase
US20210369724A1 (en) 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022515114A (ja) 2018-12-18 2022-02-17 アストラゼネカ・アクチエボラーグ 製薬方法及び中間体
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
CN114728957B (zh) * 2019-08-06 2023-09-22 无锡智康弘义生物科技有限公司 一种atr抑制剂的晶型及其应用
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4063363A4 (en) * 2019-11-21 2023-11-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PYRAZOLE HETEROARYL DERIVATIVE, PROCESS THEREOF AND MEDICAL USE THEREOF
CN112939966B (zh) * 2019-12-10 2023-03-24 武汉光谷亚太医药研究院有限公司 嘧啶衍生物、其制备及应用
TW202140474A (zh) * 2020-01-17 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2021189036A1 (en) * 2020-03-20 2021-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Taf1 inhibitors
JP2023524872A (ja) 2020-05-11 2023-06-13 アストラゼネカ・アクチエボラーグ がんの治療のためのａｔｒ阻害剤
WO2021238999A1 (zh) * 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用
CN111646985A (zh) * 2020-06-01 2020-09-11 江苏集萃分子工程研究院有限公司 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法
KR20230043109A (ko) 2020-06-24 2023-03-30 아스트라제네카 유케이 리미티드 항체-약물 접합체 및 atr 억제제의 조합
BR112023000654A2 (pt) * 2020-07-13 2023-04-25 Beijing Tide Pharmaceutical Co Ltd Composto de pirazolopirimidina usado como inibidor de atr quinase
WO2022094218A1 (en) * 2020-10-29 2022-05-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Process for the preparation of heteroaryl-substituted sulfur(vi) compounds
TW202304457A (zh) 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL306028A (en) 2021-03-26 2023-11-01 Astrazeneca Ab Combined treatment for melanoma
IT202100021863A1 (it) * 2021-08-13 2023-02-13 Univ Degli Studi Milano Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale
WO2023039573A1 (en) * 2021-09-10 2023-03-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compounds for targeted degradation of taf1
CN116283960A (zh) * 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
TW202339805A (zh) 2021-12-28 2023-10-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
HU230000B1 (en) 1999-02-10 2015-04-28 Astrazeneca Ab Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
CA2407593C (en) 2000-04-27 2011-01-11 Yamanouchi Pharmaceutical Co. Ltd. Fused heteroaryl derivatives
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
DK1335906T3 (da) 2000-11-10 2007-02-05 Hoffmann La Roche Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
TWI339204B (en) 2002-11-21 2011-03-21 Novartis Vaccines & Diagnostic Small molecule pi 3-kinase inhibitors and methods of their use
AU2004251641A1 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
BRPI0610382A2 (pt) 2005-05-20 2010-06-15 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
DE102005024494A1 (de) 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
ES2375151T3 (es) 2005-07-01 2012-02-27 Irm Llc Derivados de bencimidazol sustituidos con pirimidina como inhibidores de prote�?na cinasa.
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
US20070049603A1 (en) 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
EP1931674B1 (en) 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
CA2622352C (en) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
CA2626375A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2007063868A1 (ja) 2005-11-29 2007-06-07 Toray Industries, Inc. アリールメチレンウレア誘導体及びその用途
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
EP2008210A1 (en) 2006-03-15 2008-12-31 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
JPWO2007114323A1 (ja) 2006-04-04 2009-08-20 大正製薬株式会社 アミノピロリジン化合物
JP2009534400A (ja) 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト インダゾール化合物およびｃｄｃ７の阻害方法
JP5225076B2 (ja) 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
WO2008023180A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
WO2008047307A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
JP2010533161A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物−９４６
RU2011123672A (ru) * 2008-11-14 2012-12-20 Байер Шеринг Фарма Акциенгезельшафт Гетероароматические соединения для применения в качестве hif ингибиторов
UY32351A (es) * 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr

Also Published As

Publication number Publication date
SA111320519B1 (ar) 2014-07-02
CA2800203A1 (en) 2011-12-15
GT201200334A (es) 2014-12-22
US9155742B2 (en) 2015-10-13
PE20130306A1 (es) 2013-04-05
US8252802B2 (en) 2012-08-28
UA109010C2 (en) 2015-07-10
RS53566B1 (en) 2015-02-27
CA2800203C (en) 2019-01-22
CN103068391B (zh) 2014-11-26
ECSP12012334A (es) 2012-12-28
ZA201300255B (en) 2013-09-25
DK2579877T3 (da) 2014-10-13
SI2579877T1 (sl) 2014-11-28
NZ604480A (en) 2014-11-28
US8552004B2 (en) 2013-10-08
PT2579877E (pt) 2014-10-14
BR112012031561A2 (pt) 2016-12-06
US20110306613A1 (en) 2011-12-15
UY33440A (es) 2012-01-31
CU24109B1 (es) 2015-07-30
SMT201400146B (it) 2014-11-10
SG185711A1 (en) 2012-12-28
EP2579877B1 (en) 2014-08-13
US20160074412A1 (en) 2016-03-17
CN103068391A (zh) 2013-04-24
BR112012031561B1 (pt) 2019-12-03
ES2514325T3 (es) 2014-10-28
CU20120169A7 (es) 2014-02-28
KR20130087008A (ko) 2013-08-05
CO6640270A2 (es) 2013-03-22
US20140018364A1 (en) 2014-01-16
EA022087B1 (ru) 2015-10-30
US8999997B2 (en) 2015-04-07
MY158193A (en) 2016-09-15
CR20120628A (es) 2013-03-13
TW201201803A (en) 2012-01-16
AU2011263491A1 (en) 2013-01-24
NI201200184A (es) 2014-01-23
EA201201680A1 (ru) 2013-11-29
AU2011263491B2 (en) 2014-08-21
US20150164908A1 (en) 2015-06-18
MX2012014477A (es) 2013-06-13
HK1182019A1 (en) 2013-11-22
US20130005725A1 (en) 2013-01-03
CL2012003503A1 (es) 2013-03-08
EP2579877A1 (en) 2013-04-17
KR101820996B1 (ko) 2018-01-22
JP2013528204A (ja) 2013-07-08
TWI526208B (zh) 2016-03-21
PL2579877T3 (pl) 2015-01-30
JP5721821B2 (ja) 2015-05-20
WO2011154737A1 (en) 2011-12-15
AR081859A1 (es) 2012-10-24
HRP20140953T1 (hr) 2014-12-05
US9421213B2 (en) 2016-08-23

Similar Documents

Publication Publication Date Title
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CR11857A (es) Compuestos pirazolicos 436
UY32203A (es) Amino pirimidinas y su uso en terapia
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CU20110145A7 (es) Derivados de sulfonamida
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
NI201100130A (es) Derivados de pirimidin indol para el tratamiento de cáncer.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2015000170A (es) Compuestos químicos
UY31141A1 (es) Compuestos de piperidina y sus usos
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
UY30982A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones.
CU20100250A7 (es) Compuestos pirazólicos 436
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa